Publication date: Jul 18, 2025
All received the initial primary series of COVID-19 vaccination. Of the first group of 72,831 cancer patients studied, 69% received the monovalent COVID-19 booster, which was given before January 2022. In the first group, the monovalent booster was associated with vaccine effectiveness of 8. 5% against infection and 35. 6% against ICU admission. Currently, DORs 720-plus staff, including 73 research and staff scientists, are working on nearly 630 epidemiological and health services research projects. However, they may also be less likely to have a robust immune response to vaccination. KPDOR seeks to understand the determinants of illness and well-being and to improve the quality and cost-effectiveness of health care. Interventions to improve vaccine uptake in this high-risk population are urgently needed, they wrote. For more information, visit divisionofresearch. kp. org or follow us @KPDOR.
| Concepts | Keywords |
|---|---|
| California | Booster |
| Hospitalizations | Care |
| Pandemic | Covid |
| Scientists | Effectiveness |
| Group | |
| Hospitalizations | |
| Kaiser | |
| Md | |
| Patients | |
| Permanente | |
| Phd | |
| Received | |
| Treatment | |
| Vaccinations | |
| Vaccine |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | IDO | process |
| drug | DRUGBANK | Etoperidone |
| drug | DRUGBANK | Etodolac |
| drug | DRUGBANK | Methylphenidate |
| disease | IDO | quality |
| disease | IDO | infection |
| disease | IDO | immune response |
| disease | MESH | infections |
| disease | MESH | COVID-19 |
| disease | MESH | cancer |
| disease | MESH | infectious disease |
| pathway | REACTOME | Infectious disease |